Biogen enters into agreement with Neurimmune for Alzheimer's treatment

CAMBRIDGE, Mass. and ZURICH, Switzerland Biogen and Neurimmune Therapeutics AG have entered into an agreement for the development and commercialization of novel, full human antibodies for the treatment of Alzheimer’s disease. The partnership will focus on the development of antibodies that bind to amyloid beta, a pathogenic molecule that causes some of the symptoms in Alzheimer patients.

Neurimmune will conduct research to identify potential therapeutic antibodies using the company’s Reverse Translational Medicine platform. Biogen will be responsible for the development and commercialization of all products. Neurimmune could receive a total of $380 million in upfront and success-based milestone payments, as well as a royalty on net sales of any products.

“Biogen Idec has the manufacturing, development and commercialization capabilities to leverage our discovery and technology expertise. With their extraordinary experience in the development of biopharmaceuticals as well as their deep history in neuroscience, Biogen Idec is the perfect partner for Neurimmune,” said Edward Stuart, chief executive officer of Neurimmune. “Our RTM platform is well suited to the identification of novel, safe immunotherapies for the treatment of human disease and we are particularly proud to have entered into this deal less than one year after the founding of the company.”